UBS Group
BRTX icon

UBS Group’s BioRestorative Therapies BRTX Stock Holding History

UBS Group’s Portfolio BRTX Stock Details BRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,992
Closed -$29.2K – 10474
2026
Q1 		$27.2K Buy
+4,992
New +$64.1K ﹤0.01% 7754
2025
Q3 		– Hold
0
– -$5 – 10362
2025
Q2 		– Sell
-417
Closed -$14.5K – 10174
2025
Q1 		$14.9K Sell
417
-398
-49% -$15.3K ﹤0.01% 8409
2024
Q4 		$23.3K Buy
815
+780
+2,229% +$24.1K ﹤0.01% 7780
2024
Q3 		$1.21K Sell
35
-1,356
-97% -$44.7K ﹤0.01% 8689
2024
Q2 		$56.5K Buy
1,391
+1,349
+3,212% +$38.9K ﹤0.01% 6604
2024
Q1 		$1.16K Buy
42
+37
+740% +$1.14K ﹤0.01% 8210
2023
Q4 		$164 Buy
+5
New +$191 ﹤0.01% 8854
2023
Q3 		– Sell
-154
Closed -$7.77K – 9343
2023
Q2 		$13.6K Buy
154
+74
+93% +$7.08K ﹤0.01% 7037
2023
Q1 		$5.42K Buy
+80
New +$4.91K ﹤0.01% 8041
2022
Q4 		– Sell
-78
Closed -$4.86K – 10634
2022
Q3 		$5K Buy
78
+53
+212% +$3.29K ﹤0.01% 9170
2022
Q2 		$1K Buy
+25
New +$2.12K ﹤0.01% 9824
2022
Q1 		– Sell
-15
Closed -$1.29K – 10276
2021
Q4 		$1K Buy
+15
New +$1.71K ﹤0.01% 9956

Other funds holding BRTX

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
HRT Financial
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XTX Topco
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.2B AUM 26.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
KFGK
Keystone Financial Group (Kentucky) Lexington, Kentucky $1.69B AUM 40.17% 1-Year Est. Return

UBS Group's BRTX Position: Q2 2026 in Review

UBS Group sold out of BioRestorative Therapies (BRTX) in Q2 2026, closing a stake of 4,992 shares — an estimated $29.2K sold.

UBS Group first reported a position in BRTX in Q4 2021 and held it in 12 quarters. The position peaked at $56.5K in Q2 2024. 18 funds tracked by Wall St. Rank hold BRTX as of Q2 2026.

  • UBS Group reported no remaining BioRestorative Therapies position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 4,992 BioRestorative Therapies shares in Q2 2026, an estimated $29.2K.
  • UBS Group first reported a position in BioRestorative Therapies in Q4 2021 and held it in 12 quarters.
  • UBS Group's BioRestorative Therapies position peaked at $56.5K in Q2 2024.
  • 18 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.